Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics

Abstract

// Rui Li 1 , Xincheng Chen 1 , Yongping You 1 , Xiefeng Wang 1 , Yanwei Liu 2 , Qi Hu 1 , Wei Yan 1 1 Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China 2 Beijing Neurosurgical Institute, Capital Medical University, Beijing, China Correspondence to: Wei Yan, e-mail: neuro_yw@njmu.edu.cn Keywords: recurrent glioblastoma, primary glioblastoma, molecular characteristics, clinical features Received: March 25, 2015      Accepted: August 25, 2015      Published: September 04, 2015 ABSTRACT Glioblastoma multiforme is the most common primary malignant brain tumor in adults. In addition to poor response to treatment, a high recurrence rate contributes to the poor prognosis. The purpose of this study was to investigate the genetical and clinical characteristics of recurrent glioblastoma. We used whole transcriptome sequencing data to examine the distribution of molecular subtypes and gene signatures in 22 recurrent glioblastoma taken from the Chinese population, and further analyzed biological progression of the tumors, when compared with primary glioblastoma. The proportion of the classical subtype in recurrent ones (22%) was lower than that in primary glioblastoma (36%). The frequency of IDH1 mutations in recurrent glioblastomas was nearly twice that in primary glioblastomas. TP53 mutations were fewer in proneural recurrent glioblastomas (20%) but frequent in classical recurrent glioblastomas (80%). The most common sites of recurrent glioblastomas were the temporal lobe (41%). In patients diagnosed with recurrent glioblastoma multiforme, 64% were younger than 50 years. Gene set enrichment analysis revealed that chromatin fracture, repair, and remodeling genes were enriched in recurrent glioblastoma. Our results highlight the differences in clinical features, molecular subtypes and gene alterations between primary and recurrent glioblastoma and may be helpful for targeted therapy for recurrent glioblastoma.